Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Prime Medicine, Inc. Common Stock

Company price
3.565 USD -0.28 ( 7.16%)
Last update at 2026-11-20T21:00:00Z
VOLUME
5399197
Market Cap
569.52M

Momentum Score

…

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.49
Low
3.94
High
52 Week Price Range
2.67
Low
6.94
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
3.84
Dividend Yield
-
Revenue TTM
4.07M
Revenue Per Share
0.02
Gross Profit TTM
-142.13M
Debt / Equity
0.96
ROE
-373.29%
Net Debt
53.40M
ROCE
-65.89%
Diluted EPS TTM
-1.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -201.14M -195.88M -198.41M -122.77M -165.85M
Net income -201.14M -195.88M -198.13M -121.82M -165.37M
Selling general administrative 52.35M 50.16M 43.39M 29.82M 13.92M
Selling and marketing expenses - - 4.65M - -
Gross profit -2.69M 2.98M -4.65M 5.21M -
Reconciled depreciation 7.32M 6.13M 4.28M 2.22M 0.57M
Ebit -201.14M -195.88M -191.29M -116.54M -84.47M
Ebitda -195.76M -189.75M -186.64M -108.42M -83.52M
Depreciation and amortization 5.38M 6.13M 4.65M 8.13M 0.96M
Non operating income net other - - - -6.22M -
Operating income -208.35M -202.47M -204.79M -116.54M -84.47M
Other operating expenses 212.98M 205.45M 204.79M 116.54M 84.47M
Interest expense - - - 12.13M 81.77M
Tax provision - 0.00M -0.47M -0.95M -0.49M
Interest income 4.15M 3.52M 2.81M - -
Net interest income 4.15M 3.52M 2.81M - -
Income tax expense - - -0.28M -0.95M -0.49M
Total revenue 4.63M 2.98M 0.00M 5.21M 0.00M
Total operating expenses 205.66M 205.45M 204.79M 116.54M 84.47M
Cost of revenue 7.32M 6.13M 4.65M - -
Total other income expense net 7.21M 6.58M 6.38M -6.22M -81.38M
Net income from continuing ops -201.14M -195.88M -171.77M -121.82M -165.37M
Net income applicable to common shares - - - -142.01M -184.12M
Preferred stock and other adjustments - - - 20.19M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 342.73M 297.51M 193.85M 360.31M 301.86M
Other current assets 3.61M 21.44M 2.25M 2.70M 0.96M
Total liab 221.87M 144.36M 60.78M 360.31M 62.30M
Total stockholder equity 120.87M 153.15M 133.07M -293.58M 239.56M
Other current liab 12.60M 15.90M 1.60M 10.69M 12.30M
Common stock 0.00M 0.00M 0.00M 0.00M -
Capital stock 0.00M 0.00M 0.00M 0.00M 395.80M
Retained earnings -888.35M -687.21M -491.33M -293.20M -171.38M
Other liab - - - 0.28M 1.24M
Other assets - - - 15.14M 15.60M
Cash 63.03M 182.48M 41.57M 187.62M 185.42M
Total current liabilities 37.45M 37.96M 56.42M 26.71M 57.98M
Current deferred revenue 7.82M 7.09M 26.00M - 36.91M
Net debt 53.40M -141.68M -27.94M -158.88M -175.01M
Short term debt 8.14M 3.61M 9.28M 11.69M 7.34M
Short long term debt total 116.43M 40.79M 13.63M 28.75M 10.41M
Other stockholder equity 1009.14M 840.36M 624.41M -360.32M 15.16M
Property plant equipment - - - 19.01M 15.68M
Total current assets 181.29M 211.89M 142.98M 293.92M 270.58M
Net tangible assets - - - 316.27M -156.24M
Short term investments 114.65M 7.97M 80.09M 106.30M 84.20M
Accounts payable 8.89M 11.35M 19.54M 4.33M 1.44M
Accumulated other comprehensive income 0.08M 0.00M -0.01M -0.38M -0.03M
Common stock total equity - - - 0.00M -
Retained earnings total equity - - - -293.20M -
Non currrent assets other 14.69M 14.06M 19.73M -52.76M 15.60M
Non current assets total 161.44M 85.62M 50.88M 66.39M 31.28M
Capital lease obligations 116.43M 40.79M 13.63M 28.75M 10.41M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -104.23M 68.46M -36.26M -30.34M -68.98M
Change to liabilities - - - -23.41M 1.19M
Total cashflows from investing activities -108.76M 68.46M 18.71M -47.10M -73.63M
Total cash from financing activities 151.51M 195.88M 0.66M 181.49M 269.28M
Change to operating activities - - - -37.86M 29.99M
Net income -201.14M -195.88M -198.13M -121.82M -165.37M
Change in cash -119.81M 141.47M -146.05M 2.57M 161.57M
Begin period cash flow 196.54M 55.07M 201.12M 198.54M 36.98M
End period cash flow 76.72M 196.54M 55.07M 201.12M 198.54M
Total cash from operating activities -162.56M -122.86M -165.41M -131.83M -34.08M
Issuance of capital stock 138.39M 170.14M 0.00M 185.32M 270.36M
Depreciation 5.38M 6.13M 4.65M 2.22M 0.57M
Other cashflows from investing activities - 1.00M -0.17M -0.67M -0.50M
Sale purchase of stock - - - 181.49M -
Other cashflows from financing activities 12.00M 25.74M 0.66M -3.82M 269.28M
Change to netincome - - - 5.50M 99.54M
Capital expenditures 4.53M 7.29M 8.72M 16.09M 4.15M
Cash flows other operating - - - 5.93M -
Cash and cash equivalents changes - - - 2.57M -
Change in working capital -5.34M 31.08M 2.65M -35.40M 31.18M
Stock based compensation 29.27M 26.07M 13.91M 6.46M 1.75M
Other non cash items 9.27M 9.74M 11.79M 17.68M 98.42M
Free cash flow -167.09M -130.16M -174.14M -147.92M -38.23M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PRME
Prime Medicine, Inc. Common Stock
-0.28
7.16%
3.56 - - 139.83 0.29 155.82 -3.10
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Prime Medicine, Inc. Common Stock

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

60 First Street, Cambridge, MA, United States, 02141

617 465 0013

146

Name Title Year Born
Dr. Keith Michael Gottesdiener M.D. Pres, CEO, Sec. & Director 1954
Dr. Ann L. Lee Ph.D. Chief Technical Officer 1962
Dr. Jeremy S. Duffield M.D., Ph.D. Chief Scientific Officer 1968
Dr. Andrew Anzalone M.D., Ph.D. Co-Founder, Sr. Scientist II, Head of Prime Editing Platform & Head of Platform Devel. 1986
Dr. David R. Liu Ph.D. Co-Founder & Chair of Scientific Advisory Board NA
Ms. Carman Alenson CPA, M.B.A. Chief Accounting Officer & Interim CFO 1965
Dr. Meredith Goldwasser Sr. VP of Strategy & Corp. Operations and Head of Strategy & Corp. Operations 1971
Dr. Karen Brown J.D., Ph.D. Sr. VP of Intellectual Property & Legal Affairs NA
Ms. Niamh Alix Chief HR Officer NA
Mr. Richard Brudnick Chief Bus. Officer 1957

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…